Cala Health Wearables Shown to Decrease Tremor Movement
Real-world evidence of a Veteran Affairs (VA) patient population presented at MDS virtual congress on September 15 showcases Cala Trio as dramatically decreasing tremor movement and severity in Veterans with ET. This novel research comes on the heels of the International Essential Tremor Foundation (IETF) guidelines outlining the device in a new, recommended therapeutic category for patients with ET.
The research highlighted in the MDS Virtual Poster Tour, demonstrates Cala Trio as a viable treatment option and alternative to the more invasive and costly traditional treatment options in the marketplace for patients with ET. Key findings gathered from 58 VA patients observed during the study include:
50% of patients experienced a twofold improvement in tremor power with the month-long use of Cala Trio when used for 40-minutes on-demand.
88.1% significant tremor reduction to those with severe tremors, 83.6% improvement in patients with moderate tremor power and 79.6% improvement in mild tremor power.
Dr. Kalea Colletta of Edward Hines Jr. VA Medical Center, Department of Neurology, said: “Essential tremor is one of the most common movement disorders in adults but is unfortunately met with unsatisfactory treatment options–ineffective medications and invasive surgery. I meet with patients from all walks of life and each one deserves an easy-to-use therapy option for relief of their tremor symptoms. The evidence presented at the MDS virtual conference highlights how personalised Cala Trio is and just how impactful it can be in treating patients with mild to severe tremor symptoms.”
Cala Trio therapy, a wrist-worn device calibrated to treat tremor symptoms, delivers electrical stimulation to nerves in the wrist. These nerves project from the wrist to central brain networks that are responsible for generating hand tremor in ET. Stimulation of these nerves is thought to disrupt the central neural network causing hand tremors and provide temporary and meaningful tremor reduction in the treated hand.
Katie Rosenbluth, founder and chief science officer of Cala Health, said: “We’re proud of the acknowledgement that Cala Trio has received, from the validation from IETF as a new therapeutic area to the research presented at MDS, that proved our device as an impactful treatment for those suffering from essential tremor. We are pleased to be recognised as a viable alternative to partially effective pharmacotherapies or brain surgery, and significantly improve ET patients’ lives.”
Cala Health’s cutting-edge and science backed treatment for ET is a viable alternative to the more invasive and costly traditional treatment options in the marketplace. As part of Cala Health’s mission to make ET therapy accessible to consumers, a variety of payment options are available to meet the needs of as many patients as possible. Cala Trio is eligible as a qualified medical expense for health savings and flexible spending accounts.
Seen on Med-Tech Innovation News: Article Link